Clinical Trial

French Observatory of Congenital Ventricular Septal Defect With Pulmonary Overload

Study acronym: FRANCISCO
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
Ventricular septal defects (VSD) are the most common cardiac congenital heart defect (about 1/3 of patients with congenital heart disease). VSD management is related to hemodynamics and anatomical localization and the occurrence of complications. Small perimembranous VSD without pulmonary hypertension and without significant left to right shunting are tolerated, whereas large VSD with pulmonary hypertension require early surgical management in the first months of life. The management uncertainties concern the medium-sized perimembranous VSD causing a significant left-right shunt but without pulmonary hypertension, which are of variable treatment (surgical correction, percutaneous treatment, medical or abstention). There are no recommendations or consensus on the preferred indication of a therapeutic attitude. The Pediatric and Congenital Cardiology Subsidiary, within the French Society of Cardiology, set up an observatory of perimembranous VSD with significant shunting, without pulmonary hypertension the objectives of this study are: * To study the incidence of cardiovascular events in perimembranous VSD and search for predictive anatomical markers of events. * To study the evolution of echocardiographic and functional data of patients having percutaneous or surgical closure compared to patient managed medically. This observatory will provide a better understanding of the therapeutic algorithm in the management of VSD with pulmonary overload without pulmonary hypertension.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2017-11-30; most recent amendment 2025-02-12.
Status change: Recruiting → Active, Not Recruiting 2022-09-20
Status change: Not Yet Recruiting → Recruiting 2018-06-19
Trial Details
NCT Number NCT03363932
Lead Sponsor French Cardiology Society
Conditions Congenital Heart Disease
Enrollment 218 participants
Start Date 2018-06-01
Primary Completion 2021-12-01 (estimated)
Study Completion 2030-06 (estimated)
Updated on ClinicalTrials.gov 2025-02-13